Copyright
©The Author(s) 2018.
World J Hepatol. Nov 27, 2018; 10(11): 856-866
Published online Nov 27, 2018. doi: 10.4254/wjh.v10.i11.856
Published online Nov 27, 2018. doi: 10.4254/wjh.v10.i11.856
Table 1 Patient characteristics at treatment initiation according to virological response
Overall (n = 559) | SVR (n = 537) | Virological treatment failure (n = 22) | P value | |
Male sex | 431 (77) | 414 (77) | 17 (77) | 0.985 |
Age (yr) | 52 (49-56) | 52 (49-56) | 53 (51-57) | 0.586 |
CD4 (/mm3) (n = 557) | 618 (426-850) | 619 (429-861) | 527 (346-704) | 0.040 |
Undetectable HIV-RNA (n = 558) | 486 (87) | 469 (88) | 17 (77) | 0.186 |
ARV treatment | 549 (98) | 527 (98) | 22 (100) | 1.000 |
PI1 | 127 (23) | 122 (23) | 5 (23) | |
NNRTI2 | 98 (18) | 95 (18) | 3 (14) | |
II3 | 204 (37) | 197 (37) | 7 (32) | |
Others | 120 (22) | 113 (21) | 7 (32) | |
Active tobacco consumption (n = 263) | 153 (58) | 148 (58) | 5 (71) | 0.703 |
Active alcohol consumption (n = 266) | 135 (51) | 132 (51) | 3 (43) | 0.719 |
Active drug consumption (n = 257) | 7 (3) | 7 (3) | 0 (0) | 1.000 |
HCV genotype (n = 558) | 0.475 | |||
1 without precision | 26 (5) | 24 (5) | 2 (9) | |
1a | 232 (42) | 221 (41) | 11 (50) | |
1b | 64 (12) | 64 (12) | 0 (0) | |
2 | 6 (1) | 6 (1) | 0 (0) | |
3 | 62 (11) | 60 (11) | 2 (9) | |
4 | 165 (30) | 158 (30) | 7 (32) | |
5 | 1 (0) | 1 (0) | 0 (0) | |
6 | 2 (0) | 2 (0) | 0 (0) | |
Cirrhosis (n = 555) | 209 (38) | 200 (38) | 9 (41) | 0.748 |
Child Pugh, if cirrhosis (n = 189) | 0.537 | |||
A | 172 (91) | 165 (91) | 7 (88) | |
B/C | 17 (9) | 16 (9) | 1 (12) | |
FIB-4 (n = 405) | 2.1 (1.4-3.7) | 2.1 (1.4-3.7) | 3.3 (1.9-7.3) | 0.313 |
FIB-4 > 3.25 (n = 405) | 120 (30) | 113 (29) | 7 (50) | 0.132 |
Elastometry (kPa) (n = 115) | 9 (6-14) | 9 (6-14) | 10 (6-17) | 0.942 |
Elastometry ≥ 12.5 kPa (n = 115) | 32 (28) | 30 (27) | 2 (50) | 0.309 |
Elastometry ≥ 20 kPa (n = 115) | 17 (15) | 16 (14) | 1 (25) | 0.478 |
HCV treatment history | 0.570 | |||
Naïve | 210 (38) | 203 (38) | 7 (32) | |
Pretreated | 349 (62) | 334 (62) | 15 (68) | |
HCV viral load (log10 IU/mL) (n = 558) | 6.09 (5.59-6.51) | 6.09 (5.59-6.51) | 6.04 (5.72-6.49) | 0.886 |
Prothrombin rate (n = 298) | 99 (89-100) | 99 (89-100) | 92 (82-100) | 0.116 |
Prothrombin rate < 85% (n = 298) | 54 (18) | 50 (17) | 4 (40) | 0.087 |
Platelets (Giga/L) (n = 408) | 171 (131-219) | 171 (133-219) | 148 (97-184) | 0.168 |
Platelets < 100 Giga/L (n = 408) | 57 (14) | 51 (13) | 6 (43) | 0.007 |
Albumin (g/L) (n = 301) | 41 (38-44) | 41 (38-44) | 42 (37-45) | 0.939 |
Albumin < 35 g/L (n = 301) | 26 (9) | 24 (8) | 2 (25) | 0.146 |
DAA-combination | NA5 | |||
SOF + DCV ± RBV4 | 240 (43) | 231 (43) | 9 (41) | |
SOF/LDV ± RBV | 271 (49) | 261 (49) | 10 (46) | |
SOF + SMV ± RBV | 26 (4) | 23 (4) | 3 (14) | |
Others4 | 22 (4) | 22 (4) | 0 (0) | |
Mean (SD) DAA treatment durationa | 16 (6) | 15 (5) | 16 (6) |
- Citation: Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L, ANRS CO13 Hepavih study Group. Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients. World J Hepatol 2018; 10(11): 856-866
- URL: https://www.wjgnet.com/1948-5182/full/v10/i11/856.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i11.856